Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
NCT ID NCT07567352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the drug, any dose changes, and their overall health status. The goal is to understand how well the medicine works outside of strict clinical trial conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lorlatinib (Lorbrena)
- What this could lead to
- If successful, this study could show how well lorlatinib works outside of clinical trials, helping doctors make better treatment decisions for ALK-positive lung cancer.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient differences. It does not test a new treatment or prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart ALK-Positive lung cancer?
- New drug cocktail aims to outsmart resistant lung cancer
- Timing is everything: new study seeks best sequence for brain metastases treatment
- Antidepressant may ease brain fog from lung cancer drug
- New hope for ALK lung cancer: first human trial of AQUA07 begins
- New hope for advanced cancers? pfizer launches early trial of PF-08046033